Acetyl-l-carnitine for Dementia? Not recommended for routine use in clinical practice now

Acetyl-I-carnitine for dementia

Authors' conclusions

There is evidence for benefit of ALC on clinical global impression as a categorical measure and on MMSE at 24 weeks, but there is no evidence using objective assessments in any other area of outcome. Given the large number of comparisons made, the statistically significant results may be due to chance. 

At present there no evidence to recommend its routine use in clinical practice. 

Many of the trials used rather vague descriptions of dementia and trials using more strictly defined groups may be informative. Individual patient data may add to the findings, as would trials including other outcomes (e.g. mood and caregiver quality of life). However, the evidence does not suggest that ALC is likely to prove an important therapeutic agent. More work on the pharmacokinetics of ALC in humans is also required.

Http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003158/abstract;jsessionid=8095EC061954509CBC4F8F651A633C07.f02t01?systemMessage=Wiley+Online+Library+will+be+unavailable+on+Saturday+25th+March+from+07%3A00+GMT+%2F+03%3A00+EDT+%2F+15%3A00+SGT+for+4+hours+for+essential+maintenance.++Apologies+for+the+inconvenience.